Liskiewicz, A
Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection
Lancet 2021;397:97184.ArticlePubMed 48
In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others
[61, 62, 63, 64, 65] Based on World Health Organization (WHO), worldwide adult obesity has more than doubled since 1990, while adolescent obesity has quadrupled
BMI 27 with weight-related conditions, such as: Type 2 diabetes or prediabetes Hypertension High cholesterol Sleep apnea Fatty liver disease (NAFLD) PCOS Insulin resistance Patients in this range may be candidates because GLP-1 medications act on pathways related to blood sugar, appetite, and metabolic regulation
